
A new analyst estimate has revealed that Apple’s decision to suspend the Apple Watch Series 9 and Apple Watch Ultra 2 sales as part of a patent dispute with health company Masimo could cost the company up to $400 million in sales.
The report follows news this week that Apple will suspend online sales of its Apple Watch Series 9 and Ultra 2 starting December 21, pulling them from store shelves on December 24. The company is awaiting the deadline of a presidential review into an ITC ruling that could ban imports of both devices into the country after Apple was ruled to have infringed on patents held by Masimo in relation to the Apple Watch’s blood oxygen technology.